RXI-109

Basic Information


CAS ID: 1578261-80-9
Molecular Formula:
Molecular Weight: g/mol
Monoisotopic Mass: g/mol
Class: Unknown
Natural Product: No
Other Names:
Analysis: N/A


Compound Structure and Identifier


InChI: See All
InChI Key:
Smiles: See All
Molfile:


Related Target



Related Fibrosis Property


Trial Record 1

ClinicalTrial ID NCT02599064 Disease Subretinal fibrosis
Phase Phase 1,Phase 2 Status Active, not recruiting
First Received November 6, 2015 Last Verified February 26, 2018
Sponsor RXi Pharmaceuticals, Corp.

Trial Record 2

ClinicalTrial ID NCT01780077 Disease Scar
Phase Phase 1 Status Completed
First Received January 30, 2013 Last Verified December 3, 2014
Sponsor RXi Pharmaceuticals, Corp.

Trial Record 3

ClinicalTrial ID NCT01640912 Disease Scar
Phase Phase 1 Status Completed
First Received July 16, 2012 Last Verified September 17, 2014
Sponsor RXi Pharmaceuticals, Corp.

Trial Record 4

ClinicalTrial ID NCT02246465 Disease Hypertrophic scar
Phase Phase 2 Status Active, not recruiting
First Received September 22, 2014 Last Verified February 23, 2018
Sponsor RXi Pharmaceuticals, Corp.

Trial Record 5

ClinicalTrial ID NCT02030275 Disease Hypertrophic scar
Phase Phase 2 Status Completed
First Received January 8, 2014 Last Verified June 21, 2016
Sponsor RXi Pharmaceuticals, Corp.

Trial Record 6

ClinicalTrial ID NCT02079168 Disease Keloid
Phase Phase 2 Status Completed
First Received March 5, 2014 Last Verified June 14, 2016
Sponsor RXi Pharmaceuticals, Corp.

Related Link


PubChem:
ChEMBL: